Aprogen Healthcare & Games Inc
Aprogen Healthcare & Games Inc. engages in the development of medicines using biomedical technology. The company operates through Game Business, Rental Profit, and Pharmaceutical divisions. It offers specialty drugs, such as antibiotics, circulatory system, digestive system, anti-inflammatory, and analgesic drugs. The company also offers wireless remote lighting monitoring and control system for … Read more
Aprogen Healthcare & Games Inc (109960) - Net Assets
Latest net assets as of September 2025: ₩309.52 Billion KRW
Based on the latest financial reports, Aprogen Healthcare & Games Inc (109960) has net assets worth ₩309.52 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩324.89 Billion) and total liabilities (₩15.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩309.52 Billion |
| % of Total Assets | 95.27% |
| Annual Growth Rate | 46.86% |
| 5-Year Change | 30.18% |
| 10-Year Change | 1901.71% |
| Growth Volatility | 365.59 |
Aprogen Healthcare & Games Inc - Net Assets Trend (2013–2024)
This chart illustrates how Aprogen Healthcare & Games Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aprogen Healthcare & Games Inc (2013–2024)
The table below shows the annual net assets of Aprogen Healthcare & Games Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩301.81 Billion | +5.06% |
| 2023-12-31 | ₩287.26 Billion | +44.44% |
| 2022-12-31 | ₩198.89 Billion | -10.66% |
| 2021-12-31 | ₩222.62 Billion | -3.97% |
| 2020-12-31 | ₩231.83 Billion | +10.14% |
| 2019-12-31 | ₩210.50 Billion | -3.20% |
| 2018-12-31 | ₩217.46 Billion | +89.41% |
| 2017-12-31 | ₩114.81 Billion | +1228.34% |
| 2016-12-31 | ₩8.64 Billion | -42.68% |
| 2015-12-31 | ₩15.08 Billion | +242.49% |
| 2013-12-31 | ₩4.40 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aprogen Healthcare & Games Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8137.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩100.39 Billion | 33.26% |
| Other Components | ₩240.10 Billion | 79.55% |
| Total Equity | ₩301.81 Billion | 100.00% |
Aprogen Healthcare & Games Inc Competitors by Market Cap
The table below lists competitors of Aprogen Healthcare & Games Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EZZ Life Science Holdings Ltd
AU:EZZ
|
$7.80 Million |
|
Refinaria de Petróleos de Manguinhos S.A
SA:RPMG3
|
$7.81 Million |
|
Chemlite Innovation Berhad
KLSE:0348
|
$7.81 Million |
|
Cavitation Techs Inc
OTCQB:CVAT
|
$7.81 Million |
|
NAXS Nordic Access Buyout Fund AB
ST:NAXS
|
$7.80 Million |
|
Sundaram Brake Linings Limited
NSE:SUNDRMBRAK
|
$7.80 Million |
|
Bank Cimb Niaga Tbk
JK:BNGA
|
$7.80 Million |
|
Jaypee Infratech Limited
NSE:JPINFRATEC
|
$7.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aprogen Healthcare & Games Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 287,299,209,480 to 301,807,732,940, a change of 14,508,523,460 (5.0%).
- Net loss of 28,093,689,660 reduced equity.
- Share repurchases of 43,318,811,300 reduced equity.
- New share issuances of 43,318,811,300 increased equity.
- Other factors increased equity by 42,602,213,120.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-28.09 Billion | -9.31% |
| Share Repurchases | ₩43.32 Billion | -14.35% |
| Share Issuances | ₩43.32 Billion | +14.35% |
| Other Changes | ₩42.60 Billion | +14.12% |
| Total Change | ₩- | 5.05% |
Book Value vs Market Value Analysis
This analysis compares Aprogen Healthcare & Games Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.79x to 0.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩200.77 | ₩159.00 | x |
| 2017-12-31 | ₩1143.35 | ₩159.00 | x |
| 2018-12-31 | ₩1218.02 | ₩159.00 | x |
| 2019-12-31 | ₩1179.03 | ₩159.00 | x |
| 2020-12-31 | ₩1298.53 | ₩159.00 | x |
| 2021-12-31 | ₩6234.60 | ₩159.00 | x |
| 2022-12-31 | ₩5570.01 | ₩159.00 | x |
| 2023-12-31 | ₩2517.58 | ₩159.00 | x |
| 2024-12-31 | ₩1503.37 | ₩159.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aprogen Healthcare & Games Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -171.30%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.11x
- Recent ROE (-9.31%) is above the historical average (-33.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -83.33% | -17.72% | 1.71x | 2.75x | ₩-4.11 Billion |
| 2015 | -16.95% | -22.99% | 0.41x | 1.80x | ₩-4.06 Billion |
| 2016 | -263.22% | -231.64% | 0.63x | 1.81x | ₩-23.61 Billion |
| 2017 | -2.87% | -29.35% | 0.08x | 1.23x | ₩-14.78 Billion |
| 2018 | 4.02% | 49.72% | 0.07x | 1.09x | ₩-13.00 Billion |
| 2019 | -3.21% | -30.84% | 0.10x | 1.04x | ₩-27.80 Billion |
| 2020 | 4.78% | 107.42% | 0.04x | 1.02x | ₩-12.10 Billion |
| 2021 | 1.19% | 31.49% | 0.04x | 1.02x | ₩-19.61 Billion |
| 2022 | -2.82% | -58.41% | 0.04x | 1.07x | ₩-25.50 Billion |
| 2023 | 1.50% | 26.89% | 0.05x | 1.10x | ₩-24.43 Billion |
| 2024 | -9.31% | -171.30% | 0.05x | 1.11x | ₩-58.27 Billion |
Industry Comparison
This section compares Aprogen Healthcare & Games Inc's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,196,506,488
- Average return on equity (ROE) among peers: -9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aprogen Healthcare & Games Inc (109960) | ₩309.52 Billion | -83.33% | 0.05x | $7.80 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |